BioSpace News Archive

Exclusive Collaboration Utilizes Pandion’s Platform to Discover Novel Tissue-Specific Immunomodulators for Type 1 Diabetes and Other Autoimmune Diseases of the Pancreas

Adamas Pharmaceuticals, Inc. announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced that it will report its third quarter 2019 financial results and corporate highlights on Wednesday, November 6, 2019 before the open of the U.S. financial markets.

Diplomat Pharmacy, Inc. will release its third-quarter 2019 operating results before market open Tuesday, Nov. 12.

Campaign to raise awareness and drive change as part of Lung Cancer Awareness Month activities

COCRYSTAL PHARMA, INC., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced it intends to offer shares of its common stock for sale in an underwritten public offering.

Veloxis Pharmaceuticals A/S announced that it is raising its Outlook for 2019.

Personalis, Inc., a leader in advanced genomics for cancer, announced it will release its third quarter 2019 financial results after the market closes on Wednesday, November 13, 2019.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019.